Analysis of clinicopathological parameters illustrated that the expression of RPS27A in tumor tissues ≥ 6.0 cm was remarkably lower in contrast with that in tumor tissues < 6.0 cm and was remarkably lower in T3/4 stage patients in contrast with that in T1/2 stage patients (P < 0.01). This evidence concerns the gene RPS27A and neoplasm.